Copyright
©The Author(s) 2016.
World J Dermatol. Feb 2, 2016; 5(1): 57-64
Published online Feb 2, 2016. doi: 10.5314/wjd.v5.i1.57
Published online Feb 2, 2016. doi: 10.5314/wjd.v5.i1.57
Table 1 Demographic characteristics of subjects enrolled in pharmacokinetic studies
| Healthy volunteers PK study (n = 32) | PPR subjects maximal use PK study(n = 17) | |
| Age (yr) | ||
| Mean ± SD | 30 ± 8 | 54 ± 12 |
| (Min-max) | (18-45) | (35–74) |
| Gender (male/female) | 16/16 | 6/11 |
| IGA score: 4 (n %) | NA | 17 (100%) |
| Inflammatory lesion count | ||
| Mean ± SD | NA | 40.5 ± 14.3 |
| (Min-max) | (27.0-88.0) |
- Citation: Benkali K, Rony F, Graeber M, Jacovella J, Chappuis JP, Peirone MH, Poncet M, Delage S, Bouer R, Wagner N. Clinical pharmacokinetics profile of ivermectin 1% cream after dermal applications on the face. World J Dermatol 2016; 5(1): 57-64
- URL: https://www.wjgnet.com/2218-6190/full/v5/i1/57.htm
- DOI: https://dx.doi.org/10.5314/wjd.v5.i1.57